254 related articles for article (PubMed ID: 23771513)
1. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
2. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.
Xiang H; Bender BC; Reyes AE; Merchant M; Jumbe NL; Romero M; Davancaze T; Nijem I; Mai E; Young J; Peterson A; Damico-Beyer LA
Clin Cancer Res; 2013 Sep; 19(18):5068-78. PubMed ID: 23894056
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
[TBL] [Abstract][Full Text] [Related]
4. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
[TBL] [Abstract][Full Text] [Related]
7. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
Nnane IP; Xu Z; Zhou H; Davis HM
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):219-25. PubMed ID: 25683750
[TBL] [Abstract][Full Text] [Related]
8. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
[TBL] [Abstract][Full Text] [Related]
10. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
[TBL] [Abstract][Full Text] [Related]
12. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A.
Gupta P; Kamath AV; Park S; Chiu H; Lutman J; Maia M; Tan MW; Xu M; Swem L; Deng R
MAbs; 2016 Jul; 8(5):991-7. PubMed ID: 27031797
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
[TBL] [Abstract][Full Text] [Related]
15. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
16. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
[TBL] [Abstract][Full Text] [Related]
17. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Camidge DR; Herbst RS; Gordon MS; Eckhardt SG; Kurzrock R; Durbin B; Ing J; Tohnya TM; Sager J; Ashkenazi A; Bray G; Mendelson D
Clin Cancer Res; 2010 Feb; 16(4):1256-63. PubMed ID: 20145186
[TBL] [Abstract][Full Text] [Related]
18. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
[TBL] [Abstract][Full Text] [Related]
19. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
